title: EBV-related lymphomas: new approaches to treatment.
abstract: In the treatment of Epstein-Barr virus (EBV)-related lymphomas, there are few therapies specifically targeted against the latent virus within these tumors; in most cases the treatment approach is not different than the approach to EBV-negative lymphomas. Nonetheless, current and emerging therapies focused on exploiting aspects of EBV biology may offer more targeted strategies for EBV-positive lymphomas in the future. Conceptually, EBV-specific approaches include bolstering the antiviral/antitumor immune response with vaccines or EBV-specific cytotoxic T-lymphocytes, activating lytic viral genes to render the tumor cells susceptible to antiviral therapies, and inhibiting the downstream prosurvival or antiapoptotic pathways that may be activated by latent EBV proteins. EBV-specific cytotoxic T-cell infusions have proven effective in EBV-related posttransplantation lymphoproliferative disorder (EBV-PTLD) and expanding such adoptive immunotherapies to other EBV-related malignancies is an area of active research. However, other EBV-related lymphomas typically have more restricted, less immunogenic arrays of viral antigens to therapeutically target with adoptive immunotherapy compared with EBV-PTLD. Furthermore, the malignant EBV-positive tumor cells of Hodgkin lymphoma are scattered amid a dense infiltrate of regulatory T-cells, macrophages, and other cells that may dampen the antitumor efficacy of adoptive immunotherapy. Strategies to overcome these obstacles are areas of ongoing preclinical and clinical investigations. Some emerging approaches to EBV-related lymphomas include the coupling of agents that induce lytic viral replication with antiherpesvirus agents, or the use of small molecule inhibitors that block signaling pathways that are constitutively activated by EBV. EBV vaccines seem most promising for the treatment or prevention of EBV-related malignancies, rather than the prevention of primary EBV infection. EBV vaccine trials in patients with residual or low-bulk EBV-related malignancies or for the prevention of EBV-PTLD in EBV-seronegative patients awaiting solid organ transplantation are ongoing.
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Cancer Research Building 1, Room 389, Baltimore, MD 21287, USA.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Kanakry
authors.forename: Richard F
authors.initials: RF
authors.lastname: Ambinder
mesh_terms: D000956:Antigens, Viral / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000276:immunology / Q000628:therapy* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy* / Q000821:virology*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology; D017735:Virus Latency / Q000187:drug effects / Q000276:immunology; D014779:Virus Replication / Q000187:drug effects / Q000276:immunology
chemical_list: D000956:Antigens, Viral; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D014765:Viral Vaccines
references.citation: J Immunol. 2007 Jan 1;178(1):111-21
references.pmid: 17182546
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008
references.pmid: 16946104
references.citation: Methods Mol Biol. 2010;651:119-30
references.pmid: 20686964
references.citation: Blood. 2007 Aug 15;110(4):1123-31
references.pmid: 17468341
references.citation: Clin Cancer Res. 2012 Mar 15;18(6):1611-8
references.pmid: 22271878
references.citation: J Virol. 2000 Feb;74(3):1101-13
references.pmid: 10627520
references.citation: Blood. 2011 Jun 9;117(23):6297-303
references.pmid: 21447826
references.citation: Blood. 2010 Feb 4;115(5):925-35
references.pmid: 19880495
references.citation: Blood. 2012 Jan 26;119(4):1008-17
references.pmid: 22160379
references.citation: Blood. 2011 Apr 21;117(16):4315-22
references.pmid: 21300977
references.citation: Am J Clin Pathol. 2012 Oct;138(4):568-78
references.pmid: 23010712
references.citation: J Virol. 2008 Sep;82(17):8520-8
references.pmid: 18579586
references.citation: Blood. 2010 Dec 2;116(23):4894-905
references.pmid: 20716772
references.citation: Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9
references.pmid: 17670934
references.citation: Blood. 2008 Feb 15;111(4):2230-7
references.pmid: 18006696
references.citation: Lab Invest. 2007 Jan;87(1):29-39
references.pmid: 17075574
references.citation: Transpl Infect Dis. 2009 Oct;11(5):383-92
references.pmid: 19558376
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):460-4
references.pmid: 16428487
references.citation: Invest New Drugs. 2013 Jun;31(3):567-75
references.pmid: 23143779
references.citation: J Infect Dis. 2007 Dec 15;196(12):1749-53
references.pmid: 18190254
references.citation: Transpl Int. 2003 Mar;16(3):202-6
references.pmid: 12664217
references.citation: Invest New Drugs. 2010 Aug;28(4):413-20
references.pmid: 19471857
references.citation: Blood. 2009 Nov 26;114(23):4784-91
references.pmid: 19759356
references.citation: Nat Rev Clin Oncol. 2012 Sep;9(9):510-9
references.pmid: 22801669
references.citation: Int J Cancer. 2010 May 15;126(10):2479-89
references.pmid: 19816947
references.citation: Blood. 2010 Nov 18;116(20):4360-7
references.pmid: 20625005
references.citation: Transplant Proc. 2009 Apr;41(3):901-3
references.pmid: 19376384
references.citation: J Virol. 2008 Feb;82(3):1448-57
references.pmid: 18032491
references.citation: J Virol. 2012 May;86(10):5412-21
references.pmid: 22398289
references.citation: J Biol Chem. 2011 Oct 28;286(43):37368-78
references.pmid: 21908615
references.citation: Chin J Cancer. 2012 Jun;31(6):287-94
references.pmid: 22257383
references.citation: J Biol Chem. 2003 Feb 7;278(6):3694-704
references.pmid: 12446712
references.citation: Blood. 2012 May 3;119(18):4129-32
references.pmid: 22343727
references.citation: Clin Cancer Res. 2012 Sep 15;18(18):5061-70
references.pmid: 22761471
references.citation: J Virol. 2012 Dec;86(24):13360-70
references.pmid: 23015717
references.citation: J Immunother. 2008 Jun;31(5):500-5
references.pmid: 18463534
references.citation: Int J Cancer. 2006 Feb 15;118(4):1065-7
references.pmid: 16114017
references.citation: Hum Gene Ther Methods. 2012 Dec;23(6):376-86
references.pmid: 23186165
references.citation: J Immunol. 2007 Dec 15;179(12):8225-34
references.pmid: 18056366
references.citation: Leuk Lymphoma. 2012 Aug;53(8):1586-91
references.pmid: 22268450
references.citation: Transplantation. 2009 Oct 27;88(8):1025-9
references.pmid: 19855249
references.citation: Int J Lab Hematol. 2010 Feb;32(1 Pt 1):e169-74
references.pmid: 19196381
references.citation: Blood. 2012 Mar 15;119(11):2644-56
references.pmid: 22138512
references.citation: Clin Cancer Res. 2011 May 1;17(9):2885-92
references.pmid: 21478335
references.citation: Clin Cancer Res. 2013 Jan 1;19(1):106-17
references.pmid: 23149818
references.citation: Blood. 2009 Nov 26;114(23):4792-803
references.pmid: 19770360
references.citation: Sci Transl Med. 2011 Nov 2;3(107):107fs7
references.pmid: 22049067
references.citation: J Virol. 2012 Jun;86(11):6146-58
references.pmid: 22491455
references.citation: PLoS One. 2012;7(8):e42610
references.pmid: 22880054
references.citation: Virology. 2011 Jul 20;416(1-2):86-97
references.pmid: 21605886
references.citation: J Clin Oncol. 2013 Jan 1;31(1):39-48
references.pmid: 23169501
references.citation: Clin Cancer Res. 2012 Aug 1;18(15):4183-90
references.pmid: 22675173
references.citation: Transplantation. 2007 Apr 27;83(8):1114-21
references.pmid: 17452903
references.citation: Vaccine. 2007 Jun 11;25(24):4697-705
references.pmid: 17485150
references.citation: Blood. 2009 Mar 12;113(11):2442-50
references.pmid: 18971421
references.citation: Am J Hematol. 2012 Mar;87(3):258-65
references.pmid: 22213215
references.citation: Lancet. 1995 Jan 7;345(8941):9-13
references.pmid: 7799740
references.citation: Blood. 2009 Mar 12;113(11):2508-16
references.pmid: 18981293
references.citation: Blood. 2007 Mar 15;109(6):2571-8
references.pmid: 17119113
references.citation: Mol Med Rep. 2012 Sep;6(3):477-82
references.pmid: 22735892
references.citation: Blood. 2012 Sep 6;120(10):2003-10
references.pmid: 22826562
references.citation: Bone Marrow Transplant. 2009 May;43(10):757-70
references.pmid: 19043458
references.citation: Cancer Lett. 2007 Mar 8;247(1):77-83
references.pmid: 16647201
references.citation: Cell Cycle. 2007 Jun 1;6(11):1379-85
references.pmid: 17507800
references.citation: J Virol. 2013 Feb;87(3):1301-11
references.pmid: 23152522
references.citation: Mol Ther. 2012 Aug;20(8):1622-32
references.pmid: 22801446
references.citation: Oncogene. 2009 Mar 19;28(11):1471-6
references.pmid: 19182823
references.citation: Clin Cancer Res. 2012 Apr 15;18(8):2164-72
references.pmid: 22371452
references.citation: Blood. 2012 Nov 1;120(18):3750-5
references.pmid: 22972983
references.citation: Blood. 2010 Apr 1;115(13):2578-85
references.pmid: 19965662
references.citation: Antiviral Res. 2012 Jul;95(1):49-56
references.pmid: 22609829